DKN 01

Drug Profile

DKN 01

Alternative Names: DKN-01; LY-2812176

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Leap Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action DKK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Phase I Biliary cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 11 Oct 2016 Leap Therapeutics completes enrolment in its phase I trial for Biliary cancer (Combination therapy) in USA (IV) before October 2016 (NCT02375880),
  • 08 Oct 2016 Top-line efficacy and adverse events data from a phase I trial in Biliary cancer (Combination therapy, Treatment-experienced, Treatment-naive) released by Leap Therapeutics (IV)
  • 30 Jun 2016 Efficacy and safety data from a phase I trial in Oesophageal cancer released by Leap Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top